This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation [Investor's Business Daily]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Investors Business Daily
Related news Xencor ( XNCR ) stock popped to a record high Tuesday on investor excitement for the biotech company's inflammation and cancer drugs, though it reported no revenue for the second quarter. In midday trading on the stock market today , Xencor stock jumped 15.1%, near 43.50. Earlier, shares rose as much as 18.7%, touching an all-time high. At the same time, biotech stocks crept up a fraction. Shares of partner Novartis ( NVS ) were flat. For its second quarter, Xencor reported a loss of 46 cents per share vs. the estimate of analysts polled by Zacks for a 55-cent loss. This widened from a loss of 17 cents in the year-ago period. Xencor had $555.4 million in cash and equivalents, which should be sufficient into 2023. Most of the excitement seemed to stem from upcoming catalysts. Xencor plans to have data from tests of lupus and leukemia drugs in the fourth quarter. It also plans to begin an inflammation study and file to begin studies of cancer drugs later this year. But Ins
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Plamotamab Clinical Trials Global Bispecific Antibodies Market Drug Sales Report 2029 [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ: XNCR) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) [Yahoo! Finance]Yahoo! Finance
- Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) [Yahoo! Finance]Yahoo! Finance
- Interleukin-2 (IL-2) Inhibitor Drug Pipeline Research Report 2024 [Yahoo! Finance]Yahoo! Finance
XNCR
Earnings
- 2/27/24 - Miss
XNCR
Sec Filings
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- 3/12/24 - Form 4
- XNCR's page on the SEC website